


Claims:

1. A compound of formula I



wherein

X is =CR⁰- or =N-;

each of R⁰, R¹, R², R³ and R⁴ independently is hydrogen; hydroxy; C₁-C₈alkyl; C₂-C₈alkenyl; C₃-C₈cycloalkyl; C₃-C₈cycloalkyl-C₁-C₈alkyl; hydroxyC₁-C₈alkyl; C₁-C₈alkoxyC₁-C₈alkyl; hydroxyC₁-C₈alkoxyC₁-C₈alkyl; arylC₁-C₈alkyl which optionally may be substituted on the ring by hydroxy, C₁-C₈alkoxy, carboxy or C₁-C₈alkoxycarbonyl;

or R³ and R⁴ form together with the nitrogen and carbon atoms to which they are attached a 5 to 10 membered heterocyclic ring and comprising additionally 1, 2 or 3 heteroatoms selected from N, O and S;

or each of R¹, R² and R³, independently, is halogen; halo-C₁-C₈alkyl; C₁-C₈alkoxy; halo-C₁-C₈alkoxy; hydroxyC₁-C₈alkoxy; C₁-C₈alkoxyC₁-C₈alkoxy; aryl; arylC₁-C₈alkoxy; heteroaryl; heteroaryl-C₁-C₄alkyl; 5 to 10 membered heterocyclic ring; nitro; carboxy; C₂-C₈alkoxycarbonyl; C₂-C₈alkylcarbonyl; -N(C₁-C₈alkyl)C(O)C₁-C₈alkyl; -N(R¹⁰)R¹¹; -CON(R¹⁰)R¹¹; -SO₂N(R¹⁰)R¹¹; or -C₁-C₄-alkylene-SO₂N(R¹⁰)R¹¹; wherein each of R¹⁰ and R¹¹ independently is hydrogen; hydroxy; C₁-C₈alkyl; C₂-C₈alkenyl; C₃-C₈cycloalkyl; C₃-C₈cycloalkyl-C₁-C₈alkyl; C₁-C₈alkoxyC₁-C₈alkyl; hydroxyC₁-C₈alkoxyC₁-C₈alkyl; hydroxyC₁-C₈alkyl; (C₁-C₈alkyl)-carbonyl; arylC₁-C₈alkyl which optionally may be substituted on the ring by hydroxy, C₁-C₈alkoxy, carboxy or C₂-C₈alkoxycarbonyl; or 5 to 10 membered heterocyclic ring;


or R¹ and R² form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl residue comprising one or two heteroatoms selected from N, O and S; or

each of R⁵ and R⁶ independently is hydrogen; halogen; cyano; C₁-C₈alkyl; halo-C₁-C₈alkyl; C₂-C₈alkenyl; C₂-C₈alkynyl; C₃-C₈cycloalkyl; C₃-C₈cycloalkylC₁-C₈alkyl; C₅-C₁₀arylC₁-C₈alkyl; each of R⁷, R⁸ and R⁹ is independently hydrogen; hydroxy; C₁-C₈alkyl; C₂-C₈alkenyl; halo-C₁-C₈alkyl; C₁-C₈alkoxy; C₃-C₈cycloalkyl; C₃-C₈cycloalkylC₁-C₈alkyl; arylC₁-C₈alkyl;

- 2 -

-Y-R¹² wherein Y is a direct bond or O and R¹² is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring comprising 1, 2 or 3 heteroatoms selected from N, O and S; carboxy; (C₁-C₆alkoxy)-carbonyl; -N(C₁-C₆alkyl)-CO-NR¹⁰R¹¹; -CONR¹⁰R¹¹; -N(R¹⁰)(R¹¹); -SO₂N(R¹⁰)R¹¹; R⁷ and R⁸ or R⁸ and R⁹, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring; and wherein at most one of R¹, R² or R³ is -CON(R¹⁰)R¹¹ or -SO₂N(R¹⁰)R¹¹; in free form or salt form.

2. A process for the production of a compound of formula I according to claim 1, comprising the steps of reacting a compound of formula II



wherein R¹, R², R³, R⁴, R⁵, R⁶ and X are as defined in claim 1, and Y is a leaving group;

with a compound of formula III



wherein R⁷, R⁸ and R⁹ are as defined in claim 1;

and recovering the resulting compound of formula I in free form or in salt form, and, where required, converting the compound of formula I obtained in free form into the desired salt form, or vice versa.

3. A compound according to claim 1 in free form or in pharmaceutically acceptable salt form, for use as a pharmaceutical.

- 3 -

4. A pharmaceutical composition comprising a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers or diluents therefor.
5. The use of a compound of formula I according to claim 1 in free form or in pharmaceutically acceptable salt form, as a pharmaceutical for the treatment or prevention of a disease or condition in which ZAP-70, FAK and/or Syk tyrosine kinase activation plays a role or is implicated.
6. The use of a compound of formula I according to claim 1 in free form or in pharmaceutically acceptable salt form, as a pharmaceutical for the treatment or prevention of a disease or condition in which ZAP-70, FAK and/or Syk tyrosine kinase activation plays a role or is implicated.
7. A combination which comprises (a) a therapeutically effective amount of a ZAP-70, FAK and/or Syk inhibitor and (b) a second drug substance.
8. A method for treating or preventing a disease or condition in which ZAP-70, FAK and/or Syk tyrosine inhibitor activation plays a role or is implicated, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.
9. A method for treating or preventing a disease or condition in which ZAP-70, FAK and/or Syk tyrosine inhibitor activation plays a role or is implicated, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a ZAP-70, FAK and/or Syk inhibitor in combination with a second drug substance.